Whole‐body parametric <scp>PET</scp> imaging will replace conventional image‐derived <scp>PET</scp> metrics in clinical oncology

Leahy, Richard M.; Boellaard, Ronald; Zaidi, Habib

doi:10.1002/mp.13266

Cited by 8 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several new theranostic agents have been approved in a number of countries worldwide in the past few years, and more are coming. While companion diagnostic imaging and dosimetry calculations have traditionally used SPECT, PET has gained increasing favour in this role due to its improved sensitivity and quantitative accuracy, as well as the more widespread availability of longer-lived positron-emitting isotopes for PET imaging (e.g., 124 I and positron-emitting radiometals) that are suitable for dosimetry studies for longer-liver therapeutic nuclei (e.g., 131 I and beta-emitting radiometals).…”

Section: Statusmentioning

confidence: 99%

“…The SUVR, however, is a surrogate measure of radiotracer V T (the tissue:blood concentration ratio at equilibrium) that is vulnerable to significant bias, particularly after a bolus injection of reversibly-binding radiotracers when equilibrium assumptions are violated (Gunn et al 2015, Gallezot et al 2019. A major challenge is further demonstrating the importance of quantitative PET in the context of what is lost and gained by simplified alternatives and the usefulness of regional and parametric alternatives (Leahy et al 2018). As we continue to struggle with variable radiotracer kinetics, signal-to-noise, and reference region performance, while reducing imaging times to lessen participant study burden, we look forward to further advances over the next decade that will provide a new quantitative landscape for in vivo imaging.…”

Section: Advances In Science and Technology To Meet Challengesmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative PET in the 2020s: a roadmap

et al. 2021

Self Cite

View full text Add to dashboard Cite

Positron emission tomography (PET) plays an increasingly important role in research and clinical applications, catalysed by remarkable technical advances and a growing appreciation of the need for reliable, sensitive biomarkers of human function in health and disease. Over the last 30 years a large amount of the physics and engineering effort in PET has been motivated by the dominant clinical application during that period, oncology. This has led to important developments such as PET/CT, whole-body PET, 3D PET, accelerated statistical image reconstruction, and time-of-flight PET. Despite impressive improvements in image quality as a result of these advances, the emphasis on static, semiquantitative "hot spot" imaging for oncologic applications has meant that the capability of PET for quantifying biologically relevant parameters based on tracer kinetics has not been fully exploited. More recent advances, such as PET/MR and total body PET, have opened up the ability to address a vast range of new research questions from which a future expansion of applications and radiotracers appears highly likely. Many of these new applications and tracers will, at least initially, require quantitative analyses that more fully exploit the exquisite sensitivity of PET and the tracer principle on which it is based. It is also expected that they will require more sophisticated quantitative analysis methods than those that are currently available. At the same time, artificial intelligence is revolutionizing data analysis and impacting the relationship between the statistical quality of the acquired data and the information we can extract from the data. In this roadmap, leaders of the key sub-disciplines of the field identify the challenges and opportunities to be addressed over the next 10 years that will enable PET to realise its full quantitative potential, initially in research laboratories and, ultimately, in clinical practice.

show abstract

Section: Statusmentioning

confidence: 99%

Section: Advances In Science and Technology To Meet Challengesmentioning

confidence: 99%

Quantitative PET in the 2020s: a roadmap

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is because as newer generation PET scanners enable ever-higher-quality parametric PET images, they continue at the same time to push down the time needed for standard SUV PET imaging. It has thus been argued that applications need to demonstrate significantly increased value for more widespread usage of parametric PET imaging (see point-counterpoint discussion [91]). Whole/total-body parametric PET imaging certainly has significant potential and may also enable discoveries and insights into systemic disease as well systemic interactions and responses; e.g., gut-brain [92] or heart-brain [93] axes.…”

Section: B Whole-body and Total-body Parametric Imagingmentioning

confidence: 99%

PET Parametric Imaging: Past, Present, and Future

Wang

Rahmim

Gunn

2020

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

Positron emission tomography (PET) is actively used in a diverse range of applications in oncology, cardiology, and neurology. The use of PET in the clinical setting focuses on static (single time frame) imaging at a specific time-point post radiotracer injection and is typically considered as semi-quantitative; e.g., standardized uptake value (SUV) measures. In contrast, dynamic PET imaging requires increased acquisition times but has the advantage that it measures the full spatiotemporal distribution of a radiotracer and, in combination with tracer kinetic modeling, enables the generation of multiparametric images that more directly quantify underlying biological parameters of interest, such as blood flow, glucose metabolism, and receptor binding. Parametric images have the potential for improved detection and for more accurate and earlier therapeutic response assessment. Parametric imaging with dynamic PET has witnessed extensive research in the past four decades. In this article, we provide an overview of past and present activities and discuss emerging opportunities in the field of parametric imaging for the future.

show abstract

“…46 This repeatable, highly reliable, quantitative technique that does not add additional workload is of great value in differentiating malignancies from infection/inflammation, improving tumor staging assessment and accurate estimation of early treatment response. 47 In consideration of its long scan duration may influence patient throughput and comfort, whole-body dynamic PET may be used as a powerful supplement of static PET as so far, rather than replace it.…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Recent Advances in quantitative dynamic PET imaging of neuroendocrine tumors

Zheng

Zhou

2020

MRAJ

View full text Add to dashboard Cite

Dynamic positron emission tomography (PET) imaging is a standard art of molecular imaging technology for visualization and quantitative assessment of biochemical and physiopathological activity at cellular and molecular levels in humans and laboratory animals. Tracer kinetic modeling approach developed and validated in last decades is now widely used to extract parameters from dynamic PET data. In the study of neuroendocrine tumors (NETs), the kinetic parameters such as tracer uptake rate constant Ki estimated from dynamic PET with FDA approved 18 F-FDG and 68 Ga-DOTATATE tracers are suggested to improve the accuracy of NET detection, characterization, grading, staging, and predicting/monitoring NET responses to treatment including peptide receptor radionuclide therapy. The whole-body parametric Ki images generated from shortened dynamic PET using robust parametric imaging algorithm such as machine learning-based approach is potential for clinical and research in NET. In addition, dynamic PET can provide valuable information, such as biological distribution and radiation dose in tissue, in the study of new radioactive tracer in NET. It is expected that quantitative dynamic PET imaging in NET will be widely used for the imaging of somatostatin receptors and evaluation of therapeutic drugs and probes.

show abstract

Whole‐body parametric PET imaging will replace conventional image‐derived PET metrics in clinical oncology

Cited by 8 publications

References 16 publications

Quantitative PET in the 2020s: a roadmap

Quantitative PET in the 2020s: a roadmap

PET Parametric Imaging: Past, Present, and Future

Recent Advances in quantitative dynamic PET imaging of neuroendocrine tumors

Contact Info

Product

Resources

About